Revolutionizing translational potential in preclinical research

liver microscope flask graphics

Company profile

phoenixbio japan headquarter

PhoenixBio Co., Ltd. (Headquarters, Japan)

This is our largest site with 70+ employees and a continuous production of 100+ PXB-mice per week. In addition to in vivo study services for NAFLD/NASH, viral hepatitis, gene-based therapeutics, DMPK/toxicology, and custom transplantations, we also offer HBV study services at this location.

phoenixbio usa quarter

PhoenixBio USA Corporation (NYC Office)

This office is responsible for all non-Japanese clients. We complete project management, marketing, and sales from this office.

phoenixbio canada quarter

KMT Hepatech Inc., (Edmonton, Canada)

This is a production facility for PXB-mice and PXB-cells.

CMHL consortium logo

CMHL Consortium (Non-profitable Organization)

The Chimeric Mouse with a Humanized Liver (CMHL) Consortium was started by PhoenixBio to work with pharmaceutical industry and academic leaders to enhance applications and translational research using the PXB-mouse model. As of 2021, a total of 11 institutions, including eight pharmaceutical companies, are participating in the research.

Additional company information

Company Name PhoenixBio Co., Ltd.
Established March 4th, 2002
President and CEO Takashi Shimada
Fiscal term March
Capital 22.165 million USD (Mar.2021)
URL phoenixbio.com
Headquarters 3-4-1 Kagamiyama, Higashi-Hiroshima City 739-0046 Japan
PhoenixBio USA Corporation 65 Broadway, Suite 605, New York NY, 10006 USA
TEL +1-212-379-6411
FAX +1-212-379-6422
KMT Hepatech Inc.

2011-94 Street NW, Edmonton, Alberta, Canada, T6N1H1

CMHL Consortium LLC
Delaware, USA

 

Discover our products

Our Leadership

At PhoenixBio, our team strives to improve the global population’s quality of life and health through the application of our chimeric mouse model with a humanized liver. Our drive to improve the population’s health is central to the work we do to advance preclinical research and therapeutic development.

Board of Directors

Kenji Kuramoto: Chairman
Takashi Shimada: President & CEO
Yasuhiro Tamura: Executive Director of Administration
Chise Tateno-Mukaidani, Ph.D.: Executive Director of Research and Development
Masakazu Kakuni, D.V.M., Ph.D.: Executive Director (President, KMT Hepatech Inc.)
Yoshio Morikawa: Executive Director (President & CEO, PhoenixBio USA Corporation)
Yoshinori Fujii: External Director

Auditors

Masaharu Sagara: Full-time auditor
Hiromi Okana: (non-executive)
Masatsugu Ueda: (non-executive)
particles - left particles - right

Get in Touch

Contact us to find out how the PhoenixBio team could help your drug discovery and development projects today.